SCHEDULE: Madison Avenue Group Boosts CARGO Therapeutics Stake

A group of investment entities led by Eli Samaha has reported a 9.1% passive ownership stake in CARGO Therapeutics, Inc., holding over 4.19 million shares.

Summary

• Madison Avenue Partners LP, Madison Avenue International LP, EMAI Management, LLC, Madison Avenue GP, LLC, Caraway Jackson Investments LLC, and Eli Samaha (collectively, the "Reporting Persons") have disclosed a beneficial ownership of 4,193,626 shares of CARGO Therapeutics, Inc. common stock.
• This represents approximately 9.1% of the outstanding common stock of CARGO Therapeutics, Inc.
• The percentage is calculated based on 46,110,228 shares outstanding as of April 21, 2025, as disclosed in the Issuer's Annual Report on Form 8-K filed on June 20, 2025.
• The Reporting Persons share both voting and dispositive power over these 4,193,626 shares.
• The shares were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of CARGO Therapeutics, Inc.

Sentiment

Score: 7

Explanation: The disclosure of a significant 9.1% passive stake by a group of investment entities is generally viewed positively as it signals institutional confidence and potential long-term interest in the company, despite the passive nature of the investment.

Positives

• A significant institutional investor group, including Madison Avenue Partners LP and Madison Avenue International LP, has taken a substantial 9.1% stake in CARGO Therapeutics, Inc., indicating confidence in the company.
• The acquisition of over 4.19 million shares by a single group suggests a notable investment thesis and potential long-term interest.

Negatives

• The disclosed stake is passive, meaning the Reporting Persons do not intend to influence or change the control of CARGO Therapeutics, Inc., which may limit their ability to drive strategic changes.

Industry Context

This filing indicates a significant institutional investment in CARGO Therapeutics, a company operating in the biotechnology sector. Such investments are common in the biotech industry, where long-term growth potential often attracts large passive stakes from investment funds.

Stakeholder Impact

• Shareholders may view the increased institutional ownership as a positive signal, potentially leading to increased investor confidence and stability in the stock.
• The company's management might see this as validation of their current strategy, though the passive nature of the stake means no direct influence on corporate decisions is intended by these investors.

Key Dates

Recommendation

The filing indicates a substantial passive stake by a reputable investment group, which can be a positive signal for the company's long-term prospects. However, as a Schedule 13G, it does not provide operational or financial performance details to warrant a 'buy' or 'sell' recommendation. The significant institutional interest suggests that existing investors may want to 'hold' their positions, while new investors might consider further due diligence given the vote of confidence from a large investor.

Keywords

CARGO Therapeutics, Madison Avenue Partners, Institutional Ownership, Biotechnology, Healthcare, Investment, Shareholder, Passive Investment, SEC Filing, 13G